PeterE.ZageMDPh.D.

Pediatric Hematology & Oncology • La Jolla, CA

Pediatric Solid Tumor Oncology

Associate Professor in Residence, Pediatric Hematology & Oncology, University of California San Diego

Join to view full profile

Dr. Zage is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Connect with other colleagues in the same hospital or clinic
Search all U.S. specialist profiles and refer a patient
Read the latest clinical news and earn CME/CEU credits

See Dr. Zage's full profile

Already have an account?

Office
3010 Childrens Way, 2 West
3855 Health Sciences Drive, MC 0815
La Jolla, CA 92123
Phone+1 858-534-6494
Is this information wrong?

Education & Training

McGaw Medical Center of Northwestern UniversityFellowship, Pediatric Hematology/Oncology, 2002 - 2005
University of ChicagoResidency, Pediatrics, 1999 - 2002
Columbia University Vagelos College of Physicians and SurgeonsClass of 1999

Certifications & Licensure

CA State Medical License 2016 - 2025
TX State Medical License 2005 - 2025
IL State Medical License 1999 - 2017
American Board of Pediatrics Pediatric Hematology-Oncology

Clinical Trials

Zoledronic Acid (ZOMETA) With Cyclophosphamide With Neuroblastoma and Cortical Bone Involvement Start of enrollment: 2005 Apr 01
Completed
Phase 1
Doxercalciferol in Recurrent Pediatric Solid Tumors Start of enrollment: 2007 Aug 01
Terminated
Phase 1
ZD6474 Alone and in Combination With Retinoic Acid in Pediatric Neuroblastoma Start of enrollment: 2007 Sep 01
Terminated
Phase 1
Study of Nifurtimox to Treat Refractory or Relapsed Neuroblastoma or Medulloblastoma Start of enrollment: 2008 Jan 14
Completed
Phase 2
N2007-02:Bevacizumab,Cyclophosphamide,& Zoledronic Acid in Patients W/ Recurrent or Refractory High-Risk Neuroblastoma Start of enrollment: 2009 Dec 01
Completed
Phase 1
Biomarkers in Tumor Tissue Samples From Patients With Newly Diagnosed Neuroblastoma or Ganglioneuroblastoma Start of enrollment: 2000 Nov 06
Recruiting
N2007-03: Vorinostat and 131-I MIBG in Treating Patients With Resistant or Relapsed Neuroblastoma Start of enrollment: 2010 Mar 01
Completed
Phase 1
Vorinostat and Isotretinoin in Treating Patients With High-Risk Refractory or Recurrent Neuroblastoma Start of enrollment: 2010 Dec 01
Completed
Phase 1
Biomarkers in Tumor Samples From Younger Patients With Neuroblastoma Start of enrollment: 2011 Dec 01
Completed
Preventative Trial of DFMO in Patients With High Risk Neuroblastoma in Remission Start of enrollment: 2012 Jun 01
Active, not recruiting
Phase 2
Molecular-Guided Therapy for Childhood Cancer Start of enrollment: 2014 Jul 08
Completed
Not Applicable
Neuroblastoma Maintenance Therapy Trial Start of enrollment: 2016 Feb 01
Recruiting
Phase 2
Cabozantinib in Combination With 13-cis-Retinoic Acid in Children With Relapsed or Refractory Solid Tumors Start of enrollment: 2018 Aug 28
Recruiting
Phase 1
Join now to see all

Publications & Presentations

PubMed

UBE4B interacts with the ITCH E3 ubiquitin ligase to induce Ku70 and c-FLIPL polyubiquitination and enhanced neuroblastoma apoptosis.
Christophe Le Clorennec, Divya Subramonian, Yuchen Huo, Peter E Zage> ;Cell Death & Disease. 2023 Nov 13
2 citations
Eflornithine as Postimmunotherapy Maintenance in High-Risk Neuroblastoma: Externally Controlled, Propensity Score-Matched Survival Outcome Comparisons.
Javier Oesterheld, William Ferguson, Jacqueline M Kraveka, Genevieve Bergendahl, Thomas Clinch, Elizabeth Lorenzi, Don Berry, Randal K Wada, Michael S Isakoff, Don E E...> ;Journal of Clinical Oncology. 2024 Jan 1
1 citations
USP7 Inhibition Suppresses Neuroblastoma Growth via Induction of p53-Mediated Apoptosis and EZH2 and N-Myc Downregulation.
Christophe Le Clorennec, Karen Lee, Yuchen Huo, Peter E Zage> ;International Journal of Molecular Sciences. 2023 Sep 7
2 citations
Targeting the RET tyrosine kinase in neuroblastoma: A review and application of a novel selective drug design strategy.
Erica A Steen, Mariam Basilaia, William Kim, Taelor Getz, Jeffrey L Gustafson, Peter E Zage> ;Biochemical Pharmacology. 2023 Oct 1
A phase II trial of nifurtimox combined with topotecan and cyclophosphamide for refractory or relapsed neuroblastoma and medulloblastoma.
Don Eslin, Peter E Zage, Genevieve Bergendahl, Elizabeth Lewis, William Roberts, Jacqueline Kraveka, Deanna Mitchell, Michael S Isakoff, Jawhar Rawwas, Randal K Wada, ...> ;International Journal of Cancer. 2023 Sep 1
Identification of a novel gene signature for neuroblastoma differentiation using a Boolean implication network.
Peter E Zage, Yuchen Huo, Divya Subramonian, Christophe Le Clorennec, Pradipta Ghosh, Debashis Sahoo> ;Genes, Chromosomes & Cancer. 2023 Jun 1
Allele-specific expression reveals genes with recurrent cis-regulatory alterations in high-risk neuroblastoma.
Arko Sen, Yuchen Huo, Jennifer Elster, Peter E Zage, Graham McVicker> ;Genome Biology. 2022 Mar 4
8 citations
Genomic and Transcriptomic Analysis of Relapsed and Refractory Childhood Solid Tumors Reveals a Diverse Molecular Landscape and Mechanisms of Immune Evasion
Sara A. Byron, William P.D. Hendricks, Abhinav Nagulapally, Jacqueline M. Kraveka, William S. Ferguson, Valerie I. Brown, Don E Eslin, Deanna Mitchell, Albert Corneliu...> ;Cancer Research. 2021 Oct 5
5 citations
The Anti-Tumor Activity of the NEDD8 Inhibitor Pevonedistat in Neuroblastoma.
Jennifer Foster, Eveline Barbieri, Linna Zhang, Kathleen A. Scorsone, Myrthala Moreno-Smith, Peter E. Zage, Terzah M. Horton> ;International Journal of Molecular Sciences. 2021 Jun 18
5 citations
Overview and recent advances in the targeting of medulloblastoma cancer stem cells
Megan Rose Paul, Peter E. Zage> ;Expert Review of Anticancer Therapy. 2021 Jun 8
3 citations
Is high-risk neuroblastoma induction chemotherapy possible without G-CSF? A pilot study of safety and treatment delays in the absence of primary prophylactic hematopoi...
Sarah B. Whittle, Valeria Smith, Allison Silverstein, Margaret Parmeter, Charles G. Minard, M. Brooke Bernhardt, Peter E. Zage, Rajkumar Venkatramani, Jed G. Nuchtern,...> ;Pediatric Blood & Cancer. 2020 Jul 30
26 citations
Regorafenib is effective against neuroblastoma in vitro and in vivo and inhibits the RAS/MAPK, PI3K/Akt/mTOR and Fos/Jun pathways.
Divya Subramonian, Nikki Phanhthilath, Hannah Rinehardt, Sean Flynn, Yuchen Huo, Jing Zhang, Karen Messer, Qianxing Mo, Shixia Huang, Jacqueline Lesperance, Peter E. Zage> ;British Journal of Cancer. 2020 May 27
6 citations
Mechanisms of Efficacy of the FGFR1-3 Inhibitor AZD4547 in Pediatric Solid Tumor Models.
Nikki Phanhthilath, Sara Hakim, Catherine Su, Andrea Liu, Divya Subramonian, Jacqueline Lesperance, Peter E. Zage> ;Investigational New Drugs. 2020 May 20
19 citations
The potential functional roles of nme1 histidine kinase activity in neuroblastoma pathogenesis
Kevin Adam, Jacqueline Lesperance, Tony Hunter, Peter E. Zage> ;International Journal of Molecular Sciences. 2020 May 7
31 citations
A subset analysis of a phase II trial evaluating the use of DFMO as maintenance therapy for high-risk neuroblastoma
Elizabeth C. Lewis, Jacqueline M. Kraveka, William S. Ferguson, Don Eslin, Valerie I. Brown, Genevieve Bergendahl, William Roberts, Randal K. Wada, Javier Oesterheld, ...> ;International Journal of Cancer. 2020 Dec 1
9 citations
Sociodemographic and clinical characteristics associated with vitamin D status in newly diagnosed pediatric cancer patients.
Paula Aristizabal, Michael V. Sherer, Bianca P. Perdomo, Esteban Castelao, Courtney D. Thornburg, James A. Proudfoot, Elizabeth T. Jacobs, Ron S. Newfield, Peter E. Za...> ;Pediatric Hematology and Oncology. 2020 Mar 10
6 citations
Characterization of G-CSF receptor expression in medulloblastoma.
Megan Rose Paul, Yuchen Huo, Andrea Liu, Jacqueline Lesperance, Alexandra Garancher, Robert J. Wechsler-Reya, Peter E. Zage> ;Neuro-Oncology Advances. 2020 Jan 1
8 citations
The multikinase inhibitor RXDX-105 is effective against neuroblastoma in vitro and in vivo.
Sean Flynn, Jacqueline Lesperance, Andrew Macias, Nikki Phanhthilath, Megan Rose Paul, Jong Wook Kim, Pablo Tamayo, Peter E. Zage> ;Oncotarget. 2019 Oct 29
37 citations
Novel Therapies for Relapsed and Refractory Neuroblastoma.
Peter E. Zage> ;Children. 2018 Oct 31
58 citations
Maintenance DFMO Increases Survival in High Risk Neuroblastoma
Giselle Saulnier Sholler, William S. Ferguson, Genevieve Bergendahl, Jeffrey P. Bond, Kathleen A. Neville, Don Eslin, Valerie I. Brown, William Roberts, Randal K. Wada...> ;Scientific Reports. 2018 Sep 27
235 citations
Overview and recent advances in the treatment of neuroblastoma
Sarah B. Whittle, Valeria Smith, Erin E Doherty, Sibo Zhao, Scott Mathew McCarty, Peter E. Zage> ;Expert Review of Anticancer Therapy. 2017 Mar 15
16 citations
CD114: A New Member of the Neural Crest-Derived Cancer Stem Cell Marker Family.
Peter E. Zage, Sarah B. Whittle, Jason M. Shohet> ;Journal of Cellular Biochemistry. 2017 Feb 1
18 citations
The novel kinase inhibitor ponatinib is an effective anti-angiogenic agent against neuroblastoma
Sarah B. Whittle, Kalyani R. Patel, Linna Zhang, Sarah E. Woodfield, Michael Du, Valeria Smith, Peter E. Zage> ;Investigational New Drugs. 2016 Sep 1
15 citations
Nifurtimox Is Effective Against Neural Tumor Cells and Is Synergistic with Buthionine Sulfoximine.
Michael Du, Linna Zhang, Kathleen A. Scorsone, Sarah E. Woodfield, Peter E. Zage> ;Scientific Reports. 2016 Jun 10
11 citations
A Polymorphism in the FGFR4 Gene Is Associated With Risk of Neuroblastoma and Altered Receptor Degradation.
Sarah B. Whittle, Sahily Reyes, Melissa Du, Monica Gireud, Linna Zhang, Sarah E. Woodfield, Michael Ittmann, Michael E. Scheurer, Andrew J. Bean, Peter E. Zage> ;Journal of Pediatric Hematology/oncology. 2016 Mar 1
Join now to see all